Avecho Biotechnology (ASX:AVE)
ASX announcement history & article coverage
Transparent by design.
Announcments by Avecho Biotechnology (ASX:AVE) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Application for quotation of securities - AVE
Positive Phase III Interim Analysis Results Investor Webinar
Positive interim results from Phase III insomnia program
Phase III Interim Analysis Outcome Webinar
Trading Halt
Notification regarding unquoted securities - AVE
Notification of cessation of securities - AVE
Final Director's Interest Notice
Small Holding Share Sale Facility
2026 Annual General Meeting Results
Chair's Address and CEO Presentation
Resignation of Non-Executive Director
Investor Webinar Presentation
Receipt of Research & Development Tax Incentive
Avecho Receives $1.98M R&D Tax Incentive to Support Phase III CBD Insomnia Trial
Avecho completes treatment for Phase III interim analysis
Avecho completes treatment phase in Phase III insomnia trial, interim results due June 2026
Change of Director's Interest Notice x3
Application for quotation of securities - AVE
Expiry of Listed Options
Avecho raises $1.9 million from option exercises ahead of Phase III insomnia trial interim results
Application for quotation of securities - AVE
Change of Company Secretary
Letter to Optionholders - Notice of Expiry of Listed Options
March 2026 Quarterly Activities Report & Appendix 4C
Avecho exceeds Phase III trial recruitment, interim analysis on track for June, commercial deal with Sandoz in Australia
Notice of Annual General Meeting/Proxy Form